معرفی
Yuanqiang Li is an active researcher in the Faculty of Science and Engineering, focusing on innovative cancer therapeutics. His work bridges biochemistry, nanotechnology, and oncology through advanced nucleic acid engineering.
Research interests center on aptamer-DNAzyme frameworks for targeted gastric cancer therapy, with expertise in metal-nucleic acid hybrid systems. His recent publications demonstrate breakthroughs in self-delivering therapeutic platforms that eliminate traditional carrier requirements, enabling precise tumor targeting and catalytic drug activation.
Current research trends emphasize carrier-free MNAzyme delivery systems and metal-dependent nucleic acid frameworks, showing significant potential in overcoming limitations of conventional cancer treatments through room-temperature stable catalytic DNA structures.
Collaborative work spans international teams, with publications in high-impact journals demonstrating substantial scientific influence (51 combined Scopus citations). Key contributions address UN Sustainable Development Goals through biomedical innovation for improved global health outcomes.
Laboratory efforts focus on translating nucleic acid therapeutics from bench to bedside, with current projects optimizing oligonucleotide-based frameworks for clinical gastric cancer applications through interdisciplinary partnerships in molecular engineering.
